BioNTech
BioNTech SE (ˈbaɪɒnˌtek) is a German biotechnology company dedicated to the creation of active immunotherapies for treatments of serious diseases.
 | |
| Company type | Public (SE) |
|---|---|
| NASDAQ: BNTX | |
| ISIN | US09075V1026 |
| Industry | Biotechnology |
| Founded | 2008 |
| Founders |
|
| Headquarters | , Germany |
Number of locations | 8 (2022) |
Area served | Worldwide |
Key people |
|
| Products | BNT162b2 |
| Services | Immunotherapy |
| Revenue |  €17.3 billion (2022) |
| €12.6 billion (2022) | |
| €9.43 billion (2022) | |
| Total assets |  €23.3 billion (2022) |
| Total equity | €20.1 billion (2022) |
Number of employees | 4,530 (2022) |
| Website | biontech |
| Footnotes / references Biontech FY 2022 report[1] | |
It researches drugs based on messenger RNA (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases.[2] In 2020, the company started developing the BNT162b2 vaccine against SARS-CoV-2 with Pfizer[3] and Fosun.[4][5] In late 2020 BioNTech successfully developed, together with Pfizer, the RNA vaccine called BNT162b2 against COVID-19. The company said, it's vaccine efficacy was 95%. On 2 December 2020, the United Kingdom government gave permission to use BNT162b2 vaccinations in the country.[6] Later in December 2020 USA,[7] Canada[8] and the EU[9] also gave permission to use the BioNTech vaccine.
References change
- ↑ "BioNTech 2022 Annual Report (Form 20-F)". U.S. Securities and Exchange Commission. 27 March 2023. Retrieved 24 June 2023.
- ↑ Form F-1 BioNTech SE (Report). U.S. Securities and Exchange Commission. 9 September 2019. Archived from the original on 14 February 2021. Retrieved 13 October 2019.
- ↑ Lovelace Jr., Berkeley (27 July 2020). "Pfizer and BioNTech began late-stage human trial for coronavirus vaccine Monday". CNBC. Retrieved 2 August 2020.
- ↑ "BioNTech in China alliance with Fosun over coronavirus vaccine candidate". Reuters. Frankfurt. 15 March 2020. Retrieved 2 August 2020.
- ↑ Burger, Ludwig (22 April 2020). "Germany approves trials of COVID-19 vaccine candidate". Reuters. Berlin. Retrieved 2 August 2020.
- ↑ "UK medicines regulator gives approval for first UK COVID-19 vaccine". GOV.UK. 2 December 2020. Retrieved 25 January 2021.
- ↑ Commissioner, Office of the (7 January 2021). "Pfizer-BioNTech COVID-19 Vaccine Frequently Asked Questions". FDA.
- ↑ Canada, Health (9 December 2020). "Pfizer-BioNTech COVID-19 vaccine: What you should know". aem. Retrieved 25 January 2021.
- ↑ "Commission approves BioNTech/Pfizer vaccine". POLITICO. 21 December 2020. Retrieved 25 January 2021.
